Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Glob Antimicrob Resist ; 17: 117-122, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30553117

RESUMEN

OBJECTIVES: The aim of this study was to assess the rate of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) and the population structure of MRSA isolates recovered between 2000-2015 in a tertiary-care hospital in Athens, Greece. METHODS: Non-duplicate MRSA blood isolates recovered during the study period were examined. Antimicrobial susceptibility testing was performed by Kirby-Bauer and gradient strip methods. Carriage of PVL and mecA genes was examined by PCR. Genetic relatedness of the isolates was studied by SCCmec, spa and multilocus sequence typing. RESULTS: A total of 398 MRSA BSI cases were identified. A decreasing trend in incidence from 1.69/10 000 patient-days in 2000 to 1.39/10 000 patient-days in 2015 (P=0.038) and in prevalence from 64.7% to 36.4% (P=0.008), respectively, was observed, whereas the incidence of methicillin-susceptible S. aureus BSI increased. MRSA isolates exhibiting resistance to common antistaphylococcal agents (excluding glycopeptides and the newer antistaphylococcals) decreased from 84.8% in 2000 to 0% in 2011 and were progressively 'replaced' by more susceptible phenotypes. A strong association between antimicrobial resistance phenotype and molecular type was observed. The pandemic HA-MRSA clone ST239-III progressively declined in parallel with increasing isolation frequency of two clonal complexes (CCs): HA-MRSA CC5, with the majority of isolates belonging to ST5-II; and CA-MRSA CC80, represented mainly by ST80-IV-t044, PVL+. CONCLUSION: The decline in MRSA BSI rates observed in our institution was associated with changes in population structure of the organism. This decline may be related to biological properties of the prevailing MRSA clones.


Asunto(s)
Antibacterianos/farmacología , Bacteriemia/epidemiología , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Infecciones Estafilocócicas/epidemiología , Bacteriemia/microbiología , Técnicas de Tipificación Bacteriana , Infecciones Comunitarias Adquiridas/epidemiología , Grecia/epidemiología , Humanos , Incidencia , Staphylococcus aureus Resistente a Meticilina/clasificación , Pruebas de Sensibilidad Microbiana , Tipificación de Secuencias Multilocus , Prevalencia , Centros de Atención Terciaria , Factores de Tiempo
2.
Diagn Microbiol Infect Dis ; 88(4): 335-341, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28529091

RESUMEN

Our aims were to identify factors associated with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) in patients with hematological malignancies and evaluate the outcome of the affected patients. Consecutive patients with hematological malignancies who developed PA BSI were identified. Subsequently, two case-control studies were performed to evaluate the risk factors (i) for PA BSI and (ii) for carbapenem resistant (CR) PA BSI. Patients' outcome was evaluated at 28 days after the onset of bacteraemia. A total of 64 patients with PA BSI (45 caused by CS and 19 by CR organisms) and 128 without PA BSI were enrolled. Patients with rapidly fatal disease, steroid use, neutropenia or prior surgery were more likely to develop PA BSI, whereas patients with previous hospitalization and prior use of fluoroquinolones were more likely to develop CR PA BSI. The 28-day mortality rate was 35.9%. Severity of sepsis was the only independent predictor of adverse outcome.


Asunto(s)
Bacteriemia/tratamiento farmacológico , Neoplasias Hematológicas/microbiología , Infecciones por Pseudomonas/tratamiento farmacológico , Pseudomonas aeruginosa/efectos de los fármacos , Antibacterianos/uso terapéutico , Bacteriemia/microbiología , Carbapenémicos/uso terapéutico , Estudios de Casos y Controles , Farmacorresistencia Bacteriana/efectos de los fármacos , Femenino , Fluoroquinolonas/uso terapéutico , Hospitalización , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Pseudomonas/microbiología , Factores de Riesgo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA